5-aza-7-deazapurine Nucleosides for Treating Flaviviridae

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes the use of 5-aza-7-deazapurine nucleoside analogs and their derivatives for the treatment of infections caused by viruses within the Flaviviridae family, which includes hepatitis C virus (HCV), flaviviruses (such as dengue, West Nile, Zika, and yellow fever), and pestiviruses (which affect livestock). The compounds can be formulated as pharmaceutical compositions, administered as drugs, and used either alone or in combination with other antiviral agents to treat or prevent these viral infections.

Use CasesContent extracted from patent full text and abstract with AI.

• Treating human patients infected with hepatitis C virus (HCV), including chronic and acute cases.
• Developing antiviral drugs for preventing or managing infections caused by flaviviruses like dengue, Zika, West Nile, and yellow fever in humans.
• Veterinary applications for treating animals, especially livestock (e.g., cattle, pigs, sheep), infected with pestiviruses, reducing economic losses in agriculture.
• Combination therapy with other antiviral agents for improved efficacy and to limit drug resistance development in viral infections.
• Prophylactic treatments to prevent viral outbreaks in vulnerable populations or areas with endemic Flaviviridae viruses.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a new class of antiviral agents with activity against a broad range of Flaviviridae viruses, including HCV, flaviviruses, and pestiviruses.
• Potential to treat both humans and animals, addressing significant public health and economic problems.
• Ability to use these compounds alone or in combination with existing antiviral therapies, potentially improving treatment outcomes and combating resistance.
• Offers options for both treatment (post-infection) and prophylaxis (prevention), enhancing versatility in disease management.
• May exhibit improved safety and toxicity profiles over current standard therapies, as suggested by the inclusion of detailed toxicity assays in the patent.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-hepacivirus, anti-flavivirus or anti-pestivirus biologically active acyclic ester or pentofuranonucleoside that has a 5-aza-7-deazapurine nucleoside base. Also claimed are pharmaceutical compositions of the present invention that may be administered alone or in combination and/or alternation with another anti­viral agent, and a use of these nucleoside analogues in the manufacture of a medicament.